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Mitochondrial superoxide dismutase 2 (SOD2) converts superoxide anions to hydrogen peroxide and oxygen. Human data on
SOD2 protein content in chronic kidney disease (CKD) are sparse and mortality data are lacking. We investigated SOD2 protein
content in monocytes from patients with hemodialysis therapy (𝑛 = 81), CKD stage 1–5 (𝑛 = 120), and healthy controls (𝑛 = 13)
using in-cell Western assays. SOD2 protein decreased from CKD stage 1 until stage 4 whereas it increased again in stage 5 with
and without hemodialysis. SOD2 gene expression, analyzed by quantitative real-time PCR, was not significantly different between
the groups. Elevating cellular superoxide production reduced SOD2 protein content. This effect was abolished by the superoxide
dismutase mimetic Tempol. Using gelelectrophoresis and Western blot we did not detect nitrotyrosine modifications of SOD2 in
CKD. Finally, in patients with CKD stage 5 with hemodialysis therapy higher than median SOD2 protein content was associated
with higher all-causemortality. In conclusion, SOD2 protein content declined in CKDuntil stage 4 while SOD2 gene expression did
not. Increased cellular superoxide anion production might affect SOD2 protein content. In advanced CKD (stage 5) SOD2 protein
content increased again, but higher than median SOD2 protein content in these patients did not confer a survival benefit.
1. Introduction
In chronic kidney disease (CKD) oxidative stress occurs
frequently and has been proposed to be a central mechanism
in the pathogenesis of CKD progression and CKD associated
complications andmortality [1]. In particular dialysis patients
show a higher mortality, and the cardiovascular mortality
in patients with dialysis treatment is 10 to 20 times higher
compared to the general population [2]. Oxidative stress
describes the imbalance between formation of reactive oxy-
gen species, like superoxide anions and hydrogen peroxides,
and antioxidant defense systems [3]. Increased production
of reactive oxygen species due to inflammation or decreased
antioxidant capacity leads to lipid peroxidation and oxidation
of proteins, carbohydrates, and amino acids [4]. Reactive oxy-
gen species are normal by-products of cellular metabolism
[5]. It has been estimated that 1 to 3% of the oxygen
consumed by mitochondria is reduced to reactive oxygen
species such as superoxide anion which is generated by one-
electron-reduction of molecular oxygen [6, 7]. Superoxide
dismutase (SOD) catalyzes the dismutation of superoxide
anions to oxygen and hydrogen peroxide and thus represents
a major antioxidant defense mechanism [8]. In mammals,
different superoxide dismutase isoforms exist: superoxide
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dismutase 1 (SOD1, cytosolic copper-zinc superoxide dismu-
tase), superoxide dismutase 2, and superoxide dismutase 3
(SOD3, extracellular copper-zinc superoxide dismutase) (for
review see Fukai andUshio-Fukai [9]). Superoxide dismutase
2 (SOD2, manganese superoxide dismutase) is one of the
three isoforms and is located in mitochondria [10].
Early studies with mutant mouse models showed the
importance of SOD2 inmitochondria [11, 12]. In the homozy-
gous mutant mouse (Sod−/−) a complete loss of SOD2 pro-
tein results in impairment of further mitochondrial enzymes
followed by death of animals in 1 to 20 days after birth.
Heterozygous Sod2+/−mice have shown increased oxidative
stress [12].
In chronic kidney disease, contrasting results about SOD2
enzyme were reported. While in a uremic rat model Lim
et al. found reduced SOD2 protein content in the liver
Finch et al. found increased SOD2 protein in the kidney
[13, 14]. In human CKD SOD2 studies are so far limited
to gene expression analyses in peripheral white blood cells.
Akiyama et al. did not find a significant difference in SOD2
gene expression between healthy subjects and patients with
CKD or CKD and hemodialysis treatment while Zaza et
al. reported in 15 peritoneal dialysis patients a significantly
higher SOD2 gene expression compared to healthy controls
[15, 16]. SOD2 protein analyses in human CKD as well as
mortality analyses in relation to SOD2 protein content are
lacking.
We therefore investigated SOD2 protein content and gene
expression in patients with CKD and analyzed survival rates
in CKD stage 5 patients with hemodialysis therapy in relation
to SOD2 protein.
2. Materials and Methods
A total of 81 consecutive patients with chronic kidney disease
stage 5 undergoing maintenance hemodialysis, 120 patients
with chronic kidney disease stages 1–5 without hemodialysis
treatment, and 13 healthy control subjects were investigated.
Written informed consent was obtained from each subject
and ethical approval was given by the local ethics committee.
Hemodialysis patients were dialyzed 4-5 hours three times
per week using biocompatible membranes. Blood samples
from hemodialysis patients were taken before the start of the
hemodialysis session.
We investigated monocytes from peripheral blood as
these cells are of special interest in CKD patients. The mono-
cyte-macrophage lineage is involved in different pathogenic
processes in CKD: systemic inflammation [17], vascular
disease and atherosclerosis [18–21], kidney injury [22],
and impaired immune function [23]. Monocytes were
isolated from heparinized blood using superparamagnetic
polystyrene beads coated with a primary monoclonal anti-
body specific for the CD14 membrane antigen (Invitrogen
DYNAL, Norway) and washed several times in Hanks bal-
anced salt solution (HBSS).
For protein analyses byWestern blotting monocytes were
lysed in homogenization buffer (containing 50mmol/L Tris-
HCl, pH 8; 100mmol/L NaCl, 100mmol/L 𝛽-mercaptoeth-
anol, 50mmol/L NaF, 2mmol/L ethylenediaminetetraacetic
acid, and complete mini protease inhibitor cocktail (Roche
Diagnostics; Germany)); proteins were separated by 12.5%
sodium-dodecyl-sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) at 150V for 90 minutes and transferred to pure
nitrocellulose membranes (Biorad; USA). Membranes were
blocked with Odyssey blocking buffer (Licor biosciences;
USA) and incubated with primary antibodies against
superoxide dismutase 2 (SOD2) and beta-actin (Abcam).
After washing with HBSS, the membranes were incubated
with Alexa Fluor680-allophycocyanin-fluorescence-labelled
(MoBiTec, USA) or IRDye800CW-infrared fluorescent dye-
labelled (biomol, Germany) secondary antibodies. Imaging
was performed using the Odyssey infrared imaging system
(Licor biosciences; USA) at 700 nm or 800 nm emission with
an excitation wavelength of 680 nm or 780 nm, respectively.
Our experiments confirmed the specificity of the used SOD2
and beta-actin antibodies in human monocytes.
For the detection of nitrotyrosine the membranes were
blocked with Odyssey blocking buffer (Licor biosciences;
USA) and incubated with primary antibodies against nitro-
tyrosine (Chemicon, Millipore; USA). After washing with
HBSS, the membranes were incubated with horseradish per-
oxidase-conjugated anti-rabbit secondary antibodies (Dako-
Cytomation; Denmark). Visualization was performed using
the ECL chemiluminescence system (Amersham, USA).
For the quantification of SOD2 protein content we
performed in-cell Western assays of monocytes as recently
described by our group [24]. The method provides a sum
measurement for different posttranslationally modified and
nonmodified forms of a protein (protein species) that can
be detected with the primary antibody. We have proven
this concept in a publication about superoxide dismutase 1
(SOD1) protein species, where we investigated SOD1 protein
content in monocytes of CKD patients in parallel with two-
dimensional gel electrophoresis. The latter revealed that our
SOD1 sum analysis of protein content in in-cellWestern assay
covered at least 6 SOD1 protein species [25].
Human monocytes in 96 well plates were permeabi-
lized with Triton X100 and coincubated with the primary
antibodies against SOD2 and beta-actin (Abcam) for 2
hours. Afterwashing steps,monocyteswere coincubatedwith
corresponding secondary antibodies (see below) for 1 hour.
Imaging was performed at 700 nm or 800 nm emission with
an excitation wavelength of 680 nm or 780 nm. The protein
content of SOD2 was always normalized to the beta-actin
protein content of the same cells. Control experiments were
performed without incubation of primary antibodies.
For activation and inhibition experiments phorbol-
myristate-acetate (PMA, Sigma-Aldrich, final concentration
100 ng/mL) and 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-
oxyl (Tempol, Sigma-Aldrich, final concentration 100𝜇M)
were used (incubation time 3 hours).
RNA isolation, transcription, and quantitative real-time
PCR were performed according to manufacturer’s descrip-
tions (High Pure RNA Isolation Kit, Transcriptor First Strand
cDNASynthesis Kit, LightCyclerFastStart DNAMasterPlus
Oxidative Medicine and Cellular Longevity 3
Table 1: Population characteristics of subjects for superoxide dismutase 2 protein comparisons. Values are given as median (interquartile
range) or number (percent).
𝑛
Age
(years)
BMI
(kg/m2)
Gender
male (%)
Healthy controls 13 46 (41–52) 23.6 (20.6–25.2) 7 (54)
CKD stage 1 32 56 (44–67) 24.6 (22.7–28.5) 23 (72)
CKD stage 2 22 65 (57–70) 27.5 (22.7–32.3) 12 (55)
CKD stage 3 28 71 (62–80) 26.1 (22.0–28.4) 18 (64)
CKD stage 4 29 67 (60–74) 26.7 (22.6–31.0) 22 (76)
CKD stage 5 9 71 (56–75) 26.2 (24.6–30.7) 3 (33)
CKD stage 5 HD∗ 81 66 (57–73) 24.4 (22.2–28.5) 47 (58)
∗HD = hemodialysis therapy.
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Figure 1: (a) Detection of proteins SOD2 and reference protein beta-actin in monocytes by immunoblotting. (b) Representative in-cell
Western assay for quantification of SOD2 protein content in monocytes from a healthy control subject (Healthy), a patient with chronic
kidney disease (CKD), and a hemodialysis patient (HD). Upper panels show SOD2 protein content (red fluorescence); middle panels of
beta-actin (green fluorescence) and lower panels show overlay. Fluorescence intensities were analyzed in quadruplicate for each sample.
SYBR Green I Kit; Roche; Germany). The following primers
for real-time PCR were used:
SOD2/NM 000636:
F-5󸀠- ggt ggt cat atc aat cat ag -3󸀠;
R-5󸀠- agt gga ata agg ttt gtt gt -3󸀠 (260 bp);
Beta-actin/NM 001101:
F-5󸀠- aac tgc tta gca ccc ctg gc -3󸀠;
R-5󸀠- atg acc ttg ccc aca gcc tt -3󸀠 (200 bp);
The PCR conditions using a LightCycler 2.0 Instrument
(Roche Diagnostics, Germany) were as follows: 95∘C for
10min and 40 cycles of 95∘C for 10 s; 55∘C (for SOD2) or
60∘C (for beta-actin) for 10 s; and 72∘C for 10 s. Normalized
ratios of SOD2 mRNA expression were calculated relative
to housekeeping gene beta-actin mRNA expression includ-
ing efficiency correction and calibrator normalization. PCR
products were also size-fractionated on 1.0% agarose gels and
visualized by ethidium bromide staining.
2.1. Statistics. Data are given as median and interquartile
range. Data between groups were compared using Mann-
Whitney test or Kruskal-Wallis test and Dunn’s multiple
comparison posttest, as appropriate. Kaplan Meier survival
curves were compared using log-rank test (GraphPad prism
software, version 5.0, GraphPad Software, SanDiego, CA). All
statistical tests were two-sided. A two-sided value of 𝑝 less
than 0.05 was considered statistically significant.
3. Results
We investigated superoxide dismutase 2 (SOD2) protein in
monocytes from patients with chronic kidney disease (CKD)
and healthy controls using in-cell Western assays (subject
characteristics given in Table 1). First, the specificity of the
SOD2 and beta-actin antibodies used in our experiments was
shown by Western blotting (Figure 1(a)). We demonstrated
SOD2 and beta-actin protein detection in monocytes with
molecular weights of 21 kDa and 41 kDa. Figure 1(b) shows
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Figure 2: J-shaped pattern of SOD2 protein content. Quantification
of SOD2 protein content relative to housekeeping protein beta-actin
by in-cell Western assays.The figure shows the comparison between
healthy control subjects, patients with CKD stage 1 through 5, and
hemodialysis patients (CKD5 HD); ∗𝑝 < 0.05 compared to healthy
controls by Dunn’s multiple comparison posttest.
representative in-cell Western assays of SOD2 and beta-
actin protein in monocytes from healthy control subject, a
patient with CKD, and a hemodialysis patient (quadruplicate
determination for each subject).
Next, SOD2 protein content was analyzed for patients
with all CKD stages, patients with hemodialysis therapy, and
healthy controls. Figure 2 shows the summary data for SOD2
protein content which is decreased with declining glomerular
filtration rate until CKD stage 4. In contrast, patients with
CKD stage 5 without and also with hemodialysis therapy then
show again higher SOD2 protein content so that a J-shaped
pattern results. Kruskal-Wallis analysis showed a significantly
different distribution of SOD2 protein content between all
groups (𝑝 < 0.002).
In addition to quantification of the protein content,
we investigated the SOD2 gene expression in monocytes
from hemodialysis patients, patients with CKD, and healthy
control subjects. Figures 3(a) and 3(b) present typical ampli-
fication and melting curves for SOD2 mRNA and the
housekeeping gene beta-actin mRNA from a hemodialysis
patient, a patient with CKD, and a control subject. PCR
products were also size fractionated on 1.0% agarose gels
and stained by ethidium bromide (Figure 3(c)). The SOD2
mRNA expression levels from patients with CKD and healthy
control subjects are shown in Figure 4. The relative SOD2 to
beta-actin gene expression inmonocytes is expressed as ratio.
Although there seemed to be a trend to increased SOD2 gene
expression from healthy to CKD stage 4 patient the Kruskal-
Wallis analysis did not show a significant difference in the
distribution of SOD2 gene expression between the groups
(𝑝 = 0.10).
Since we did not detect changes in SOD2 gene expression
that explained the differences which we found in SOD2
protein content we investigated the effect of an increased
cellular superoxide production on SOD2 protein content
in mononuclear cells. To stimulate cellular superoxide pro-
duction mononuclear cells were treated with PMA in the
presence and absence of the SOD-mimetic Tempol. Figure 5
shows changes in SOD2 protein after cell incubation with
PMAwith and without Tempol.The protein content of SOD2
in the cells at baseline (1.00 (0.98–1.02)) was reduced after
incubation with PMA (0.82 (0.77–0.86); 𝑛 = 8) whereas
the addition of Tempol significantly increased SOD2 protein
content (1.22 (1.02–1.44; 𝑛 = 6); each 𝑝 < 0.01).
We also performed SDS-PAGE andWestern blot analyses
to search for nitrotyrosinemodifications on SOD2 proteins in
healthy subjects (H) and CKD stage 4 (CKD) and CKD stage
5 HD (HD) patients. No protein staining at the expected site
of SOD2 bands was detected by the anti-nitrotyrosine anti-
body (Supplementary Figure 1(C) in SupplementaryMaterial
available online at http://dx.doi.org/10.1155/2016/7423249).
Finally, we were interested in the relation between SOD2
protein content in monocytes of CKD stage 5 patients with
hemodialysis therapy and all-cause mortality. We divided the
patients in a groupwith SOD2protein below and a groupwith
SOD2 protein above the median (SOD2/beta actin protein =
42.54). Table 2 shows a comparison of the clinical parameter
of these two patient groups. As indicated in Figure 6 survival
was significantly better in hemodialysis patients with lower
SOD2 protein content in peripheral blood monocytes (Chi
square, 6.25; 𝑝 < 0.05 by log-rank test).
4. Discussion
We investigated SOD2 gene expression and protein content in
monocytes of CKD patients. Also, in hemodialysis patients, a
population with reportedly high all-cause and cardiovascular
mortality, we analyzed the relation between SOD2 protein
content andmortality.Themajor findings in our study are the
following: (1) SOD2 protein content showed a J-curve pattern
with significantly lower values compared to healthy controls
and a progressive reduction until CKD stage 4 followed
again by higher SOD2 protein content in CKD stage 5 and
patients with hemodialysis treatment. (2) The SOD2 gene
expressionwas not significantly different between the groups.
(3) Higher thanmedian SOD2 protein content was associated
with higher mortality in patients with hemodialysis therapy.
Both, the results on protein content and gene expression
of SOD2 in our study, are interesting. In an earlier study
our group investigated gene expression and protein content
of the cytosolic superoxide dismutase isoform (SOD1) in
monocytes of patients with CKD. In contrast to SOD2, the
SOD1 protein was reduced in CKD showing the lowest
protein content in patients with hemodialysis therapy; and
SOD1 gene expression was increased in CKD, with a high
significance in patients with hemodialysis [25]. These results
are supported by the literature. In peripheral blood mononu-
clear cells of hemodialysis patients a significant increase of
SOD1 mRNA compared to healthy controls was reported
while SOD2 mRNA did not differ significantly from control
[15]. The different gene expression of SODs in CKD could
be explained by the multiple differences in gene regulation
between SOD1 and SOD2 (for review see Miao and St. Clair
Oxidative Medicine and Cellular Longevity 5
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Figure 3: (a) Representative amplification curves of the quantitative real-time PCR for SOD2 and the housekeeping gene beta-actin in
hemodialysis patients (HD, circles), patients with chronic kidney disease (CKD, squares), and control subjects (healthy; triangles). Curves
with x-symbols indicate the no-template control in the PCR. (b) Melting analysis after amplification of SOD2 and the housekeeping gene
beta-actin.Themelting curve analysis confirmed the presence of one single peak in hemodialysis patients (HD, circles), patients with chronic
kidney disease (CKD, squares), and healthy control subjects (healthy; triangles). Curves with x-symbols indicate the no-template control in
the PCR and show a peak at lower temperature representing primer-dimers in the no-template reaction. (c) Example of size fractionation of
PCR products on 1.0% agarose gels. M denotes the base pair DNA marker, lane 1 hemodialysis patient, lane 2 CKD patient, lane 3 healthy
control, lane 4 negative control (no reverse transcriptase), and lane 5 negative control (no template). Left side shows PCR products for SOD2;
right side shows PCR products for beta-actin.
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Figure 4: SOD2 mRNA expression analyzed by quantitative real-
time PCR normalized to beta-actin in monocytes from healthy
subjects (healthy), patients with chronic kidney disease (CKD1–5),
and hemodialysis patients (CKD5 HD); 𝑝 = 0.10 in the Kruskal-
Wallis analysis.
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Figure 5: SOD2 protein content in cells under baseline conditions
(control) and after incubation with PMA to stimulate cellular
superoxide production with (𝑛 = 6) and without (𝑛 = 8) the SOD-
mimetic Tempol. ∗∗𝑝 < 0.01 versus basal.
[26]). With respect to the reduced SOD2 protein content
found in CKD stages 3 and 4 in our present study different
explanations are suggested by the literature. Two factors
in CKD can contribute to an enhanced degradation of
proteins: oxidative stress and uremia. Oxidative modification
of SOD2 proteins has been described. Our own Western
blot analyses did not suggest tyrosine nitration of SOD2 in
CKD although refined analysis requires mass-spectrometric
analyses of SOD2 protein from CKD patients and healthy
subjects. While some authors using recombinant SOD2
protein showed tyrosine nitration and tyrosine oxidation
upon treatment with peroxynitrite [27], protein biochemical
analyses of SOD2 protein species frommedulloblastoma cells
showed tryptophan oxidation and histidine oxidations but
no tyrosine nitration [28]. Therefore, it will be necessary to
analyze oxidative SOD2 modifications for each pathogenic
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SOD2 protein content larger than median
Time (months)
60483624120
0.0
0.2
0.4
0.6
0.8
1.0
Fr
ac
tio
n 
su
rv
iv
al
Figure 6: KaplanMeier survival curves of hemodialysis (CKD5HD;
𝑛 = 81) patients according to the SOD2protein content in peripheral
blood monocytes (Chi square, 6.25; 𝑝 < 0.05 by log-rank test).
condition individually. Further insights could be revealed by
adjacent analyses of SOD2 protein degradation and SOD2
enzymatic activity.
Our own results in the current study point to an involve-
ment of reactive oxygen species in the regulation of SOD2
protein content since we observed a PMA-induced decrease
of SOD2 protein inmononuclear cells that could be abolished
by treatment with the SOD-mimetic Tempol. Furthermore,
increased SOD2 protein degradation in the uremic envi-
ronment may be involved. SOD2 protein was shown to
be degraded by the ubiquitin-proteasomal pathway [29].
In CKD protein degradation via the ubiquitin-proteasomal
pathway is enhanced [30, 31]. Generally, posttranslational
protein modifications known for SOD2 from other cell
types should also be considered for monocytes. These are
tyrosine nitration and tyrosine oxidation [27], histidine and
tryptophan oxidation [28], acetylation (for review see Zou et
al. [32]), and ubiquitination [29].
Numerous studies have shown that the correlation be-
tween gene expression, quantified by messenger RNA
(mRNA) analysis, and quantification of protein content is
often limited (for review see [33, 34]). Specifically, for changes
in protein content but unaltered mRNA levels a regulation of
translation or regulatory changes of protein degradation can
be underlying mechanisms.
The following conditions for instance have been de-
scribed: reduced mRNA levels but constant protein content
[35], constant mRNA levels but reduced protein content due
to increased protein degradation [36], and constant mRNA
levels but increased protein content due to decreased protein
degradation [37]. Furthermore, our own group showed for
superoxide dismutase 1 in monocytes from chronic kidney
disease patients an increased mRNA level together with
reduced superoxide dismutase 1 protein content [25].
Themechanisms underlying the increase of SOD2protein
in advanced CKD (CKD5 with and without hemodialysis)
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Table 2: Clinical and biochemical characteristics of CKD patients with hemodialysis therapy. Values are median (interquartile range).
Characteristics Lower than median SOD2protein
Higher than median
SOD2 protein
Age (years) 66 (58–73) 66 (56–74)
Gender (male/female) 24/16 22/18
Body mass index (kg/m2) 24.4 (22.7–28.6) 24.3 (22.1–27.8)
Time since initiation of dialysis treatment (days) 244 (30–481) 295 (39–1193)
Hemoglobin (g/dL) 10.1 (9.3–11.4) 10.1 (8.6–12.0)
C-reactive protein (mg/dL) 2.7 (0.1–6.2) 2.6 (0.9–6.9)
compared to CKD 3 and 4 that we observed and that resulted
in a J-shape of SOD2 protein content are not known. In this
respect it is of interest that an upregulation of SOD2 protein
that was reported in uremic rats could be reversed by vitamin
D receptor agonists [14]. Since advanced uremia is a state
of 1,25-dihydroxyvitamin D deficiency but also of vitamin
D receptor deficiency and dysfunction, vitamin D receptor-
related uremic effects could be involved in the J-shape of
SOD2 protein that we observed [38].
Finally, we observed a better survival in hemodialysis
patients with a SOD2 protein content below the median of
this patient group compared to those with SOD above the
median. The underlying mechanism for this observation is
not known but considering the above discussed connection
to vitamin D metabolism an association of higher content
of SOD2 protein with more severe uremic disturbance of
vitamin D receptor signal transduction could be involved.
In future experiments it will be necessary to identify
underlying SOD2 protein modifications using 2 DE, mass-
spectrometry and immunoblotting.
Taken together, our study shows significant changes
of SOD2 protein content with increasing degree of renal
function impairment. We also proof, in line with our own
previous research but also with many other groups, that
in clinical-experimental research a parallel investigation of
gene expression and protein content is indispensable. And
finally, we provide the first report of SOD2 protein content
together with its association with survival in CKD patients
with hemodialysis therapy.
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